Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

11.67
+0.26002.28%
Post-market: 11.700.0300+0.26%18:15 EDT
Volume:4.53M
Turnover:52.17M
Market Cap:3.78B
PE:-21.39
High:11.73
Open:11.44
Low:11.18
Close:11.41
52wk High:12.58
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:1.14
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:4.22
PE(LYR):-23.81

Loading ...

AbCellera Biologics Adds Independent Director to Board

TIPRANKS
·
Jul 07

AbCellera apponts Lynn Seely to board of directors

TIPRANKS
·
Jul 06

Abcellera Appoints Lyell CEO Lynn Seely to Board as Independent Director

Reuters
·
Jul 06

Abcellera Appoints DR. Lynn Seely to Its Board of Directors

THOMSON REUTERS
·
Jul 06

Is AbCellera (ABCL) Using the Jazz Partnership to Quietly Redefine Its Oncology Platform Strategy?

Simply Wall St.
·
Jun 28

AbCellera Biologics call volume above normal and directionally bullish

TIPRANKS
·
Jun 25

Why AbCellera Biologics (ABCL) Is Up 5.5% After New Jazz T-Cell Engager Collaboration Agreement

Simply Wall St.
·
Jun 20

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)

TIPRANKS
·
Jun 18

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Reuters
·
Jun 17

Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact

Dow Jones
·
Jun 17

Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies

TIPRANKS
·
Jun 17

Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers

Reuters
·
Jun 17

Jazz Pharmaceuticals and Abcellera Announce Collaboration to Discover Next-Generation T-Cell Engaging Multispecific Antibodies

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Collaboration Includes $56 Mln Upfront and up to $792 Mln Option Fees per Program

THOMSON REUTERS
·
Jun 17

Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration

THOMSON REUTERS
·
Jun 17

Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions?

Simply Wall St.
·
Jun 13

AbCellera shareholders elect John Montalbano, Stephen Quake as Class III directors

Reuters
·
Jun 13

AbCellera files Form 3 for director Victor Sandor, reporting no beneficial ownership

Reuters
·
Jun 12

AbCellera Biologics Adds Victor Sandor to Board

TIPRANKS
·
Jun 06

AbCellera appoints Victor Sandor to board as independent director

Reuters
·
Jun 05